Geneos Wealth Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Geneos Wealth Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,000	Closed	-$105K	–	3038
2020 Q3	$105K	Hold	2,000	–	–	0.01%	925
2020 Q2	$107K	Hold	2,000	–	–	0.01%	893
2020 Q1	$77K	Hold	2,000	–	–	0.01%	940
2019 Q4	$72K	Hold	2,000	–	–	﹤0.01%	1084
2019 Q3	$13K	Hold	2,000	–	–	﹤0.01%	1800
2019 Q2	$18K	Hold	2,000	–	–	﹤0.01%	1697
2019 Q1	$27K	Hold	2,000	–	–	﹤0.01%	1445
2018 Q4	$21K	Hold	2,000	–	–	﹤0.01%	1495
2018 Q3	$25K	Hold	2,000	–	–	﹤0.01%	1490
2018 Q2	$26K	Hold	2,000	–	–	﹤0.01%	1351
2018 Q1	$27K	Hold	2,000	–	–	﹤0.01%	1267
2017 Q4	$11K	Hold	2,000	–	–	﹤0.01%	1620
2017 Q3	$14K	Hold	2,000	–	–	﹤0.01%	1468
2017 Q2	$18K	Hold	2,000	–	–	﹤0.01%	1326
2017 Q1	$14K	Sell	2,000 -2,000	-50%	-$14.4K	﹤0.01%	1386
2016 Q4	$29K	Hold	4,000	–	–	﹤0.01%	1041
2016 Q3	$24K	Hold	4,000	–	–	﹤0.01%	1077
2016 Q2	$18K	Hold	4,000	–	–	﹤0.01%	1157
2016 Q1	$10K	Buy	+4,000	New	+$14.6K	﹤0.01%	1321

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Geneos Wealth Management's CCXI Position: Q4 2020 in Review

Geneos Wealth Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2020, closing a stake of 2,000 shares — an estimated $105K sold.

Geneos Wealth Management first reported a position in CCXI in Q1 2016 and held it in 19 quarters. The position peaked at $107K in Q2 2020. 196 funds tracked by Wall St. Rank hold CCXI as of Q4 2020.

Geneos Wealth Management reported no remaining ChemoCentryx, Inc. position as of Q4 2020 after selling out during the quarter.
Geneos Wealth Management sold 2,000 ChemoCentryx, Inc. shares in Q4 2020, an estimated $105K.
Geneos Wealth Management first reported a position in ChemoCentryx, Inc. in Q1 2016 and held it in 19 quarters.
Geneos Wealth Management's ChemoCentryx, Inc. position peaked at $107K in Q2 2020.
196 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.